文档下载 文档下载导航
设为首页 | 加入收藏
搜索 请输入内容:  
 导航当前位置: 文档下载 > 所有分类 > 工程科技 > 电子/电路 > Serratiopeptidase A systematic review of the existing evidence
侵权投诉

Serratiopeptidase A systematic review of the existing evidence

Table 1 Evidence from clinical and preclinical studies (clinical studies). Clinical trial Condition No. of patients Study design Treatment Control Duration Outcome Sign for grading evidence 1À

212

Grading of evidence suggesting serratiopeptidase as anti-in ammatory agent Esch et al. Postoperative and 66 Randomised 19894 traumatic swelling (repair of lateral collateral ligament of knee) Postoperative and 98/group in two Randomised and Tsuyama traumatic swelling drug groups and 99 double blind et al.13 in placebo group Tachibana Postoperative buccal 174 (88 in TSP and Multicentre, et al. 198414 swelling 86 in placebo group) randomised, (Caldwell-luc double blind, antrotomy) placebo-controlled Super cial 40 (20 per group) Randomised Bracale 15 thrombophlebitis et al. 1996

Serratiopeptidase: dos

e not speci ed

Application of ice, leg elevation and bed rest

Unclear

Reduction in swelling by 50% on third postoperative day and pain disappeared by 10th day in TSP group A-4700 shown to be equally effective to Serratiopeptidase in improving symptoms and reducing swelling Buccal swelling reduced signi cantly in serratiopeptidase group 65% of TSP while 85% cases of SAP showed improvement in speci c symptoms like pain, erythema Moderate to marked improvement in breast pain, swelling and induration seen in TSP group Clinical improvement seen in 65% patients

Serratiopeptidase: dose not speci ed

A-4700 tablet and Placebo

Not stated

1À

Serratiopeptidase 10 mg thrice daily (30mg/day) Serratiopeptidase 10 mg thrice daily (30mg/day) Serratiopeptidase: 10mg thrice daily (30 mg/day) Serratiopeptidase: 10 mg twice daily with initial short course of nimesulide e

Placebo

7 days

1þ

S. Bhagat et al./ International Journal of Surgery 11 (2013) 209e217

Seaprose S (SAP) 30 mg thrice daily (90mg/day) Placebo

14 days

1þ

Kee et al. 19895

Breast engorgement

70 (35 per group)

Randomised, double blind

3 days

1þ

REVIEW

Panagariya et al. 19997

Carpel tunnel syndrome

20 patient

Prospective trial

e

6 weeks

2À

e

Back pain, migraine

No randomised controlled trials

e

e

e

e

e

Grading of evidence for its use in otorhinolaryngology pathologies Acute or chronic ear, 193 (about 96 per Mazzone nose or throat disorder group) et al. 19901

Multicentre, randomised, double blind, placebo-controlled

Serratiopeptidase (2 tablets of 5 mg) thrice daily, i.e., 30 mg/day

Placebo (2 tablets thrice daily)

7e8 days

Bellussi et al. 1984

Secretory otitis media 16

75

Nagaoka et al. 197917

Chronic respiratory disease with dif cult in expectoration Chronic respiratory disease (not bronchial asthma) Chronic sinusitis

Shimura et al. 198318 Majima et al. 198819

376 patients (125 in Seaprose S, 128 in TSP and 123 in placebo group) 40 (<10/group)

Randomised and double blind (for 50 patients) Multicentre, randomised, double-blind, double dummy Randomised

Serratiopeptidase (0.5 mg/kg/day) Serratiopeptidase (10 mg thrice daily)

Placebo

10 days

Seaprose S (15 mg thrice daily) and placebo

14 days

Serratiopeptidase 30 mg/day Serratiopeptidase 30 mg/day

e

Prospective, open label

Various mucolytic agents as comparator e

7 days

TSP showed good ef cacy in reducing symptoms like severity of pain, amount and purulence of secretions, dif culty in swallowing, nasal dysphonia and obstruction and anosmia Unde ned global judgement Numerous tests but outcomes unclear No signi cant difference between two groups in showing improvement in expectoration and speci c symptoms Relaxation of sputum viscoelasticity TSP reduced the viscosity of mucus but not its elasticity

1þ

1À

1þ

1À

4weeks

2À

Serratiopeptidase A systematic review of the existing evidence

上一页第4页

你可能喜欢

热门文档

相关文档

站点地图 | 文档上传 | 侵权投诉 | 手机版
本站所有资源均来自互联网,本站只负责收集和整理,均不承担任何法律责任,如有侵权等其它行为请联系我们.
文档下载 Copyright 2013 doc.guandang.net All Rights Reserved.  -  email